Abstract
Alcohol addiction or alcoholism is the most severe form of problem drinking. A variety of treatment methods for alcoholism are currently available that combine medications, behavioral treatment and peer support. The drugs that are currently approved by the U.S. Food and Drug Administration (FDA) for treatment of alcohol dependence are disulfiram, naltrexone and acamprosate. For many patients, however, these treatments are not effective. Evidence from a number of studies suggests that various factors, both psychosocial and economic, as well as genetic variation, are significant contributors to interindividual variation both of clinical presentation of alcohol problems and response to a given treatment. The aim of the present review is to summarize and discuss different aspects of personalized medicine of alcohol addiction. We focus on pharmacogenomics and beyond, to include the genetics and epigenetics of alcohol addiction as well as other psychosocial and even economic factors that may affect response to alcohol addiction pharmacotherapy. It is anticipated that, within the next 5-10 years, personalized medicine of alcohol addiction will be a reality and it will help reduce the burden of alcoholism from society and increase the well-being and productivity of individuals addicted to alcohol.
Keywords: Alcohol, addiction, disulfiram, naltrexone, acamprosate, pharmacogenetics, personalized drug treatment.
Current Pharmaceutical Biotechnology
Title:Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond
Volume: 18 Issue: 3
Author(s): Georgia Ragia and Vangelis G. Manolopoulos*
Affiliation:
- Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Dragana Campus, 68100 Alexandroupolis,Greece
Keywords: Alcohol, addiction, disulfiram, naltrexone, acamprosate, pharmacogenetics, personalized drug treatment.
Abstract: Alcohol addiction or alcoholism is the most severe form of problem drinking. A variety of treatment methods for alcoholism are currently available that combine medications, behavioral treatment and peer support. The drugs that are currently approved by the U.S. Food and Drug Administration (FDA) for treatment of alcohol dependence are disulfiram, naltrexone and acamprosate. For many patients, however, these treatments are not effective. Evidence from a number of studies suggests that various factors, both psychosocial and economic, as well as genetic variation, are significant contributors to interindividual variation both of clinical presentation of alcohol problems and response to a given treatment. The aim of the present review is to summarize and discuss different aspects of personalized medicine of alcohol addiction. We focus on pharmacogenomics and beyond, to include the genetics and epigenetics of alcohol addiction as well as other psychosocial and even economic factors that may affect response to alcohol addiction pharmacotherapy. It is anticipated that, within the next 5-10 years, personalized medicine of alcohol addiction will be a reality and it will help reduce the burden of alcoholism from society and increase the well-being and productivity of individuals addicted to alcohol.
Export Options
About this article
Cite this article as:
Ragia Georgia and Manolopoulos G. Vangelis*, Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond, Current Pharmaceutical Biotechnology 2017; 18 (3) . https://dx.doi.org/10.2174/1389201018666170224105025
DOI https://dx.doi.org/10.2174/1389201018666170224105025 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proteome and Metabolome Alterations in Heart and Liver Indicate Compromised Energy Production During Sepsis
Protein & Peptide Letters Potential Application of Centrifuges to Protect the CNS in Space and on Earth
Current Alzheimer Research Association of SORL1 Alleles with Late-Onset Alzheimer's Disease. Findings from the GIGAS_LOAD Study and Mega-Analysis
Current Alzheimer Research BST-2 Expression in Human Hepatocytes is Inducible by All Three Types of Interferons and Restricts Production of Hepatitis C Virus
Current Molecular Medicine Editorial (Hot Topic: Monoamine Oxidase as a Target in Medicinal Chemistry and Drug Discovery)
Current Topics in Medicinal Chemistry Age-related Changes in Respiratory Function and Daily Living. A Tentative Model Including Psychosocial Variables, Respiratory Diseases and Cognition
Current Aging Science Radionuclide Molecular Imaging Using Affibody Molecules
Current Pharmaceutical Biotechnology Neuroleptics and Migraine
Central Nervous System Agents in Medicinal Chemistry <i>In-silico</i> Studies and Biological Activity of Potential BACE-1 Inhibitors
Combinatorial Chemistry & High Throughput Screening Role of Nitric Oxide in Neurodegeneration: Function, Regulation, and Inhibition
Current Neuropharmacology Approaches to Stabilize Amorphous Form - A Review
Current Drug Therapy Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
Central Nervous System Agents in Medicinal Chemistry Expression of Opioid Receptors During Peripheral Inflammation
Current Topics in Medicinal Chemistry An fMRI Study of the Neural Systems Involved in Visually Cued Tactile Top-Down Spatial and Temporal Attention
Neuroscience and Biomedical Engineering (Discontinued) Arylpiperazine Derivatives Acting at 5-HT1A Receptors
Current Medicinal Chemistry Hospital-Based Tobacco Interventions in Pediatric Settings
Current Pediatric Reviews MicroRNAs in Genetic Disease: Rethinking the Dosage
Current Gene Therapy NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimers Disease
Current Pharmaceutical Design Deep Brain Stimulation: A New Treatment in Mood and Anxiety Disorders
CNS & Neurological Disorders - Drug Targets Neuropsychiatric Disturbances in Alzheimer’s Disease: What Have We Learned from Neuropathological Studies?
Current Alzheimer Research